The U.S. FDA accepted Dimension Therapeutics Inc.'s investigational new drug application for DTX301 to treat ornithine transcarbamylase deficiency, a genetic disorder that causes ammonia to accumulate in the blood.

Dimension expects to start a phase 1/2 clinical trial to evaluate the urea cycle disorder drug in patients with the deficiency by the end of 2016.